Botulinum toxin type A has been established as a therapeutic agent in spasticity, dystonia, and cosmetic indications for several decades. Its application to postsurgical pain has developed more slowly, and the reasons span both preclinical and clinical domains. The peripheral mechanisms of BoNT analgesia are reasonably characterized in the literature. The central contributions are less clearly defined, and the behavioral and affective dimensions of postsurgical recovery have proven difficult to capture in animal models. A 2022 paper by Cornet et al. in Scientific Reports addressed several of these gaps within a single experimental design, expanding the evidentiary basis on which sponsors can support a BoNT candidate for a postsurgical indication.
The study evaluated abobotulinumtoxinA (DYSPORT) in the porcine skin and muscle incision with retraction (SMIR) model in the lower back. The SMIR variant was selected for specific methodological reasons. It produces a clinically relevant injury profile incorporating both nociceptive and inflammatory components, alongside a measurable distress behavior profile that more transient incisional models tend to obscure. Dosing was intraoperative and intradermal, with three doses of abobotulinumtoxinA (100U, 200U, 400U), liposomal bupivacaine as a comparator, and saline as control.
Mechanical allodynia, assessed by von Frey, was fully reversed from Day 3 onward across all three abobotulinumtoxinA doses. Liposomal bupivacaine produced analgesia over the first several hours after surgery, with declining effect through Day 1, consistent with its established profile in this model. The distress behavior score, an instrument that quantifies spontaneous postsurgical discomfort behaviors in pigs, normalized within six hours of surgery in the abobotulinumtoxinA arms. These endpoints are directly relevant to sponsor decision making. They provide a Phase II planning team with defensible measurements of duration of effect and onset, both of which can be benchmarked against existing standards of care.
The mechanistic readouts strengthen the case further. SNAP25 cleavage was confirmed in the dorsal horn, demonstrating that abobotulinumtoxinA reached central synaptic terminals and acted upon them, rather than acting solely on peripheral afferents. Spinal cord histology demonstrated reduced GFAP and Iba1 immunoreactivity, indicating attenuation of astrocyte and microglial activation, both established correlates of central sensitization. For a BoNT product, these readouts are significant because they extend the evidentiary case beyond peripheral block and into central modulation, where chronic pain risk originates.
The most novel component of the study is the behavioral observation. AbobotulinumtoxinA, in this model, reduced pain associated anxiety and depression like reactivity. As the authors note, this represents the first demonstration of a botulinum toxin reducing affective correlates in a postsurgical model. The finding is meaningful for two reasons. First, the affective overlay of acute postsurgical pain is increasingly recognized as a driver of poor recovery and prolonged opioid exposure, and clinical practice is evolving to address it. Second, multidimensional pain measurement is increasingly incorporated into the design of postsurgical pain clinical trials, and preclinical packages that address these dimensions integrate more directly with the clinical development plan. Anxiety and depression like outcomes in pigs do not translate one to one with human affective experience, but in a model already demonstrating concordance with human surgical pain, they constitute supportive evidence within a defensible preclinical package.
The porcine SMIR model was an appropriate experimental platform for several reasons. Pig skin is structurally and functionally similar to human skin across thickness, hair follicle content, pigmentation, collagen, and lipid composition, which provides a defensible early read on topical, intraoperative, or intradermal administration in human surgery. Pigs also display observable spontaneous pain behaviors. The distress behavior score, the human approach test, and the open field paradigm were developed specifically for an animal that visibly responds to discomfort, which provides face validity for affective readouts.
The SMIR variant in the lower back contributes additional value. It generates the mixed nociceptive and inflammatory profile characteristic of human surgical recovery, rather than the more transient signature produced by a simple skin incision. For a drug development program targeting a postsurgical indication, this profile aligns more closely with the indication than a Brennan model in a rat.
Sponsors developing BoNT therapeutics for surgical pain are operating in a market that already includes approved non opioid options for short duration analgesia, including liposomal bupivacaine and the bupivacaine meloxicam ER combination. The competitive question is no longer whether a candidate can produce 24 to 72 hours of analgesia, but whether it can meaningfully extend the analgesic window, modify the central sensitization trajectory, and reduce the affective burden of surgical recovery. The 2022 abobotulinumtoxinA study demonstrated that a porcine SMIR package can address all three questions in a single experiment. This level of integrated evidence generation is what development teams require when scoping a Phase II design and anticipating the regulatory and clinical questions that will arise.
For sponsors evaluating BoNT, gel based local anesthetics, or other postsurgical pain candidates, MD Biosciences runs validated porcine pain models (SI, SMI, SMIR, and Göttingen minipig hind leg POP) alongside rodent comparator work where appropriate. Endpoints include von Frey mechanical allodynia, the distress behavior score, the human approach test, open field with AnyMaze tracking, electrophysiology (SNCV, cMAP, SNAP), intraepidermal nerve fiber density, dorsal horn histology and biomarker readouts (SNAP25, GFAP, Iba1), and integrated pharmacokinetics from the same animals. The same package supported the original ZYNRELEF translational case, the ALX005 oleogel bupivacaine work published in 2024, and the DYSPORT study described here.
For questions about study design for a BoNT or postsurgical pain candidate, contact neuro@mdbiosciences.com.
References:
Cornet S et al. 2022. Intraoperative abobotulinumtoxinA alleviates pain after surgery and improves general wellness in a translational animal model. Scientific Reports. https://doi.org/10.1038/s41598-022-25002-x
Castel D et al. 2017. Local and topical analgesic activity in domestic pig models of postoperative pain. Journal of Pain Research.
Meijs S et al. 2021. A systematic review of porcine models in translational pain research. Lab Animal.